



Pergamon

Tetrahedron Letters 40 (1999) 8089–8091

---

---

TETRAHEDRON  
LETTERS

---

---

## Synthesis and stability study of the new pentammonio lipid pcTG90, a gene transfer agent

Abdesslame Nazih,<sup>a</sup> Yves Cordier,<sup>b</sup> Rainer Bischoff,<sup>b,†</sup> Hanno V. J. Kolbe<sup>b</sup> and  
Denis Heissler<sup>a,\*</sup>

<sup>a</sup>Université Louis Pasteur et Centre National de la Recherche Scientifique, Institut de Chimie, BP 296, 67008 Strasbourg,  
France

<sup>b</sup>TRANSGENE S.A., 11 rue de Molsheim, 67082 Strasbourg, France

Received 20 August 1999; accepted 2 September 1999

---

### Abstract

The cationic lipid pcTG90 has been prepared from (*S*)-1-aminopropane-2,3-diol by *N*-acylation with *N*-protected 18-amino-3,7,11,15-tetraaazooctadecanoic acid and *O*-acylation with oleic acid. The former acid could be obtained from 1,3-propanediamine via tetraprotected caldopentamine. The stability of the cationic lipid in HEPES buffer has been studied. © 1999 Elsevier Science Ltd. All rights reserved.

*Keywords:* polyamines; amphiphilic compounds.


---

In the course of our program on the design, synthesis, and evaluation of new cationic lipids for gene transfer,<sup>1</sup> we have shown on a family of amphiphilic triacylglycerols with tri-, tetra-, and pentammonio polar heads that the highest transfection efficacy in *in vitro* assays could be obtained with the lipid **pcTG56**, in which glycerol bears two oleoyl groups and a pentammonio polar head.<sup>2</sup> However, this compound showed slow degradation in the 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer solution used for formulation studies. The hydrolysis of the *sn*-3 ester function seemed to be involved since 1,2-dioleoyl glycerol was identified among the degradation products. Therefore, we have decided to prepare the amide analogue **pcTG90** in which the same polar head is linked to the hydrophobic moiety of the molecule by an amide function which we expected to be more resistant to hydrolysis. Since *in vivo* tests required multigram amounts of cationic lipids, we have also worked out a shorter and more efficient synthesis for **pcTG90** than the one used for **pcTG56**.<sup>2</sup>


---

\* Corresponding author. Fax: +33 388 41 68 59; e-mail: heissler@chimie.u-strasbg.fr

† Present address: AstraZeneca plc, Department of Cell and Molecular Biology, PO Box 34, 22100 Lund, Sweden.



The preparation of **pcTG90** required first the obtention of the *N*-protected pentamino acid **5** and hence that of the tetraprotected caldopentamine **4**.<sup>3</sup> By subjecting commercially available 1,3-propanediamine **1** to the three-step sequence — cyanoethylation, *t*-butoxycarbonyl (Boc) protection of the amines, and reduction of the cyano groups — described earlier by Meinwald,<sup>4,5</sup> we obtained the diprotected thermine **2** (Scheme 1). This compound could then be monocyanoethylated by reaction with one equivalent of acrylonitrile and, after treatment with ditertiobutyl dicarbonate, gave the nitrile **3** which was reduced to the amine **4**<sup>6</sup> by catalytic hydrogenation on Raney nickel. This sequence furnished **4** in 43% overall yield from **1** on a multigram scale and was found to be more convenient than other syntheses of such tetraprotected pentamines.<sup>7</sup> Three additional steps in one pot — imine formation by reaction of amine **4** with glyoxylic acid, catalytic hydrogenation on palladium, and protection of the resulting secondary amine with Boc — led to the *N*-protected pentamino acid **5**<sup>6</sup> in 73% yield.



Scheme 1. (a)  $\text{CH}_2=\text{CHCN}$  (2.0 equiv.), EtOH, rt, 16 h (yield: 88%); (b)  $(\text{Boc})_2\text{O}$  (2.2 equiv.),  $(i\text{-Pr})_2\text{NEt}$  (2.0 equiv.), rt, 4 h (98%); (c)  $\text{H}_2$  (gas bag), Raney Ni, EtOH, NaOH (2.5 equiv.), rt, 16 h (88%); (d)  $\text{CH}_2=\text{CHCN}$  (1.0 equiv.; dropwise addition), EtOH,  $0^\circ\text{C}$ , then rt, 16 h; then concentrate in vacuo and add  $(\text{Boc})_2\text{O}$  (2.2 equiv.),  $(i\text{-Pr})_2\text{NEt}$  (2.0 equiv.), THF, rt, 3 h (63%); (e)  $\text{H}_2$  (gas bag), Raney Ni, EtOH, NaOH (1.5 equiv.), rt, 16 h (91%); (f)  $\text{OHC-CO}_2\text{H}$  (1.1 equiv.), MeOH, rt, 0.5 h; then  $\text{H}_2$  (gas bag), 10% Pd/C, rt, 4 h; then flush with Ar and add  $(\text{Boc})_2\text{O}$  (1.5 equiv.),  $(i\text{-Pr})_2\text{NEt}$  (1.5 equiv.), rt, 3 h (73%); (g) *N*-hydroxysuccinimide (1.1 equiv.), DCC (1.1 equiv.), dioxane, rt, 16 h; then  $(S)$ -1-aminopropane-2,3-diol (2.0 equiv.) in DMF, rt, 2 h (79%); (h) oleic acid (2.2 equiv.), DCC (2.2 equiv.), DMAP (0.1 equiv.),  $\text{CH}_2\text{Cl}_2$ , rt, 16 h (62%); (i)  $\text{CF}_3\text{CO}_2\text{H}:\text{CH}_2\text{Cl}_2$  (1:1, v/v),  $0^\circ\text{C}$ , 3 h (91%)

The synthesis of **pcTG90** was then undertaken from  $(S)$ -1-aminopropane-2,3-diol, prepared by treatment of commercially available  $(R)$ -glycidol with cold aqueous ammonia.<sup>8</sup> *N*-Acylation with acid **5**, activated as its *N*-succinimidyl ester, and *O*-acylation with oleic acid in the presence of 1,3-dicyclohexylcarbodiimide (DCC) led to compound **7**<sup>6</sup> which, by removal of the Boc protecting groups, gave **pcTG90**.<sup>9</sup>

Stability studies consisting of the storage of **pcTG56** and of **pcTG90** in HEPES buffer at  $4^\circ\text{C}$  and at  $21^\circ\text{C}$  for variable periods of time and in the determination of the percentage of recovered cationic lipid were carried out.<sup>10</sup> They showed a higher stability at room temperature for **pcTG90** than for **pcTG56** (Table 1). **pcTG90** was also tested as a gene transfer agent and exhibited high levels of transfection activity in vitro and in vivo.<sup>11</sup>

Table 1  
Percentage of recovered **pcTG56** and **pcTG90** after storage in HEPES buffer

Storage time (days)	Recovered <b>pcTG56</b> after storage at 4°C	Recovered <b>pcTG56</b> after storage at 21°C	Recovered <b>pcTG90</b> after storage at 4°C	Recovered <b>pcTG90</b> after storage at 21°C
5	94%	66%	95%	98%
15	93%	37%	91%	95%
33	80%	11%		94%

## References

1. For a recent review on gene transfer with cationic lipids, see: Miller, A. D. *Angew. Chem., Int. Ed. Engl.* **1998**, *37*, 1768–1785.
2. Unpublished results from these laboratories.
3. This compound has been reported so far only in the patent literature: Saccomano, N. A.; Volkmann, R. A. PCT Int. Appl. WO 93 04,036; *Chem. Abstr.* **1993**, *119*, 117123j.
4. McCormick, K. D.; Kobayashi, K.; Goldin, S. M.; Reddy, N. L.; Meinwald, J. *Tetrahedron* **1993**, *49*, 11155–11168.
5. In our hands, reduction of the cyano groups by catalytic hydrogenation on Raney nickel (Bergeron, R. J.; Garlich, J. R. *Synthesis* **1984**, 782–784) gave better yields than those reported by Meinwald for the reduction with  $\text{LiAlH}_4$ .
6.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ). Amine **4**:  $\delta$  1.43 and 1.45 (2 s, 36H, *t*-Bu-), 1.60–1.82 (m, 8H, -N(Boc)- $\text{CH}_2$ - $\text{CH}_2$ -), 2.71 (m, 2H, - $\text{CH}_2$ - $\text{NH}_2$ ), 3.02–3.35 (m, 14H, -N(Boc)- $\text{CH}_2$ -). Acid **5**:  $\delta$  1.44 (br s, 45H, *t*-Bu-), 1.58–1.84 (m, 8H, -N(Boc)- $\text{CH}_2$ - $\text{CH}_2$ -), 3.02–3.38 (m, 16H, -N(Boc)- $\text{CH}_2$ -), 3.86 and 3.94 (2 m, 2H, - $\text{CH}_2$ - $\text{CO}_2\text{H}$ ). Lipid **7**:  $\delta$  0.88 (t,  $J=6.4$  Hz, 6H, Me-), 1.27 and 1.29 (2 br s, 40H, - $\text{CH}_2$ -), 1.43, 1.44 and 1.46 (3 s, 45H, *t*-Bu-), 1.53–1.82 (m, 12H, -O-C(O)- $\text{CH}_2$ - $\text{CH}_2$ - and -N(Boc)- $\text{CH}_2$ - $\text{CH}_2$ -), 2.00 (m, 8H, - $\text{CH}_2$ -CH=), 2.30 (t,  $J=7.5$  Hz, 4H, -O-C(O)- $\text{CH}_2$ -), 3.02–3.30 (m, 16H, -N(Boc)- $\text{CH}_2$ -), 3.50 (m, 2H, - $\text{CH}_2$ -NH-C(O)-), 3.81 (br s, 2H, -NH-C(O)- $\text{CH}_2$ -N(Boc)-), 4.10 and 4.25 (2 dd,  $J=12.1$ , 5.8, 4.0 Hz, 2H, - $\text{CH}_2$ -O-C(O)-), 5.08 (m, 1H, > $\text{CH}$ -O-C(O)-), 5.34 (m, 4H, -CH=).
7. Jasys, V. J.; Kelbaugh, P. R.; Nason, D. M.; Philips, D.; Rosnack, K. J.; Saccomano, N. A.; Stroh, J. G.; Volkmann, R. A. *J. Am. Chem. Soc.* **1990**, *112*, 6696–6704. Geall, A. J.; Blagbrough, I. S. *Tetrahedron Lett.* **1998**, *39*, 443–446.
8. Sowden, J. C.; Fischer, H. O. L. *J. Am. Chem. Soc.* **1942**, *64*, 1291–1293.
9. Lipid **pcTG90**:  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ - $\text{CF}_3\text{CO}_2\text{D}$ )  $\delta$  0.87 (t,  $J=6.4$  Hz, 6H, Me-), 1.27 and 1.28 (2 br s, 40H, - $\text{CH}_2$ -), 1.58 (m, 4H, -O-C(O)- $\text{CH}_2$ - $\text{CH}_2$ -), 2.00 (m, 8H, - $\text{CH}_2$ -CH=), 2.12–2.46 (m, 12H, - $\text{NH}_2^+$ - $\text{CH}_2$ - $\text{CH}_2$ - and -O-C(O)- $\text{CH}_2$ -), 3.20 (m, 16H, - $\text{NH}_2^+$ - $\text{CH}_2$ -), 3.50 (m, 2H, -C(O)-NH- $\text{CH}_2$ -), 3.98 (m, 2H, - $\text{NH}_2^+$ - $\text{CH}_2$ -C(O)-NH-), 4.23 (m, 2H, - $\text{CH}_2$ -O-C(O)-), 5.20 (m, 1H, > $\text{CH}$ -O-C(O)-), 5.34 (m, 4H, -CH=). FAB-MS (*m*-nitrobenzyl alcohol)  $m/z$  905.9 (100%,  $[\text{M}+\text{H}]^+$ ); 677.6 (27%,  $[\text{M}-\{\text{H}(\text{NHCH}_2\text{CH}_2\text{CH}_2)_4\}+2\text{H}]^+$ ); 620.6 (82%,  $[\text{M}-\{\text{NH}_2(\text{CH}_2\text{CH}_2\text{CH}_2\text{NH})_4\text{CH}_2\text{C}(\text{O})\}+2\text{H}]^+$ ); 356.4 (78%,  $[\text{M}-\{\text{NH}_2(\text{CH}_2\text{CH}_2\text{CH}_2\text{NH})_4\text{CH}_2\text{C}(\text{O})\}$ -oleoyl group+3H] $^+$ ); 283.3 (75%, [oleic acid+H] $^+$ ). M stands for  $\text{C}_{53}\text{H}_{104}\text{N}_6\text{O}_5=904.8$ .
10. The cationic lipid (2 mg) was dissolved in 1:1 dimethylsulfoxide:ethanol (40  $\mu\text{l}$ ) and 20 mM HEPES buffer (pH 7.5, 160  $\mu\text{l}$ ) was added. Aliquots (20  $\mu\text{l}$ ) of this solution were stored in sealed tubes: one series was kept at 4°C and another at 21°C. After dilution with isopropanol (40  $\mu\text{l}$ ), vortexing, and addition of 99.9:0.1 water: $\text{CF}_3\text{CO}_2\text{H}$  (40  $\mu\text{l}$ ), they were analysed by HPLC (Supelcosil ABZ+Plus column; elution with mixtures of 0.15%  $\text{CF}_3\text{CO}_2\text{H}$  in water (A) and 0.05%  $\text{CF}_3\text{CO}_2\text{H}$  in isopropanol (B): 50% A/50% B for 8 min, then 50% to 100% B gradient for 12 min, then 100% B for 10 min; detection at 205 nm).
11. Schughart, K.; Bischoff, R.; Ali Hadji, D.; Boussif, O.; Perraud, F.; Accart, N.; Rasmussen, U. B.; Pavirani, A.; van Rooijen, N.; Kolbe, H. V. *J. Gene Ther.* **1999**, *6*, 448–453.